Strategy

Formycon Reports BLA Resubmission Strategy for FYB201 (biosimilar, ranibizumab)

  • by

Shots: Formycon & Bioeq reported the BLA resubmission strategy for FYB201 (biosimilar referencing Lucentis) has been adjusted With the revised submission strategy, the companies expect a simplification of the approval procedure. The modified submission dossier is anticipated to be filed with the US FDA in… Read More »Formycon Reports BLA Resubmission Strategy for FYB201 (biosimilar, ranibizumab)

Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team

  • by

Prescient hires three new senior members to strengthen and grow its Intelligence & Insight business LONDON, July 15, 2020—Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta, Rob… Read More »Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team